Evidence map›Paper›PMID 38203319›Full record

ArticleInternational journal of molecular sciences2023

Activation and Functions of Col6a1+ Fibroblasts in Colitis-Associated Cancer.

Niki Chalkidi, Maria-Theodora Melissari, Ana Henriques, Athanasia Stavropoulou, George Kollias, Vasiliki Koliaraki

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Niki ChalkidiInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Centre (BSRC) "Alexander Fleming", 16672 Vari, Greece.
Maria-Theodora MelissariInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Centre (BSRC) "Alexander Fleming", 16672 Vari, Greece.ORCID 0000-0001-5154-2801
Ana HenriquesInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Centre (BSRC) "Alexander Fleming", 16672 Vari, Greece.ORCID 0000-0002-2421-4308
Athanasia StavropoulouInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Centre (BSRC) "Alexander Fleming", 16672 Vari, Greece.
George KolliasInstitute for Bioinnovation, Biomedical Sciences Research Centre (BSRC) "Alexander Fleming", 16672 Vari, Greece.
Vasiliki KoliarakiInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Centre (BSRC) "Alexander Fleming", 16672 Vari, Greece.ORCID 0000-0003-1694-6987
Alexander Fleming Biomedical Sciences Research Center · GRNational and Kapodistrian University of Athens · GR

Funding

Worldwide Cancer Research 22-0126
6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) comprise a group of heterogeneous subpopulations with distinct identities indicative of their diverse origins, activation patterns, and pro-tumorigenic functions. CAFs originate mainly from resident fibroblasts, which are activated upon different stimuli, including growth factors and inflammatory mediators, but the extent to which they also maintain some of their homeostatic properties, at least at the earlier stages of carcinogenesis, is not clear. In response to cytokines, such as interleukin 1 (IL-1) and tumor necrosis factor (TNF), as well as microbial products, CAFs acquire an immunoregulatory phenotype, but its specificity and pathophysiological significance in individual CAF subsets is yet to be determined. In this study, we analyzed the properties of Col6a1-positive fibroblasts in colitis-associated cancer. We found that Col6a1+ cells partly maintain their homeostatic features during adenoma development, while their activation is characterized by the acquisition of a distinct proangiogenic signature associated with their initial perivascular location. In vitro and in vivo experiments showed that Col6a1+ cells respond to innate immune stimuli and exert pro-tumorigenic functions. However, Col6a1+-specific inhibition of TNF receptor 1 (TNFR1) or IL-1 receptor (IL-1R) signaling does not significantly affect tumorigenesis, suggesting that activation of other subsets acts in a compensatory way or that multiple immune stimuli are necessary to drive the proinflammatory activation of this subset. In conclusion, our results show that adenoma-associated CAF subsets can partly maintain the properties of homeostatic fibroblasts while they become activated to support tumor growth through distinct and compensatory mechanisms.

Indexed as

AdenomaCancer-Associated FibroblastsColitis-Associated NeoplasmsCarcinogenesisCollagen Type VIFibroblastsHumansTumor Necrosis Factor-alphaCol6a1 protein, humanCollagen Type VITumor Necrosis Factor-alphacolon cancerheterogeneityintestinal fibroblasts

Identifiers

PMID38203319
PMCPMC10778587
OpenAlexW4390061466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.